GLP 1 Receptor Agonists & SGLT 2 Inhibitors: Emerging Evidence for Alzheimer’s Disease Prevention

Manuscript Summaries

By NATHAN

Published on 02 September 2025

Background:

The Intersection of Metabolic Disease and Neurodegeneration

Type 2 diabetes mellitus (T2DM) and neuroinflammation share critical pathophysiological pathways with Alzheimer’s disease (AD) and Parkinson’s disease (PD). Chronic hyperglycemia, insulin resistance, vascular dysfunction, and systemic inflammation are known contributors to cognitive decline.

Among second-line antidiabetic agents, glucagon-like peptide‑1 (GLP‑1) receptor agonists and sodium–glucose cotransporter‑2 (SGLT‑2) inhibitors stand out for their cardiometabolic and potential neuroprotective benefits. Preclinical studies suggest they may reduce neuroinflammation, amyloid beta (Aβ) accumulation, and tau hyperphosphorylation, and improve autophagy and mitophagy function—mechanisms implicated in AD progression.

Study Objective & Rationale

Given mixed results from prior observational studies, this research aimed to rigorously evaluate the comparative effects of GLP‑1 RAs, SGLT‑2 inhibitors, and dipeptidyl peptidase‑4 (DPP‑4) inhibitors on the onset of AD and PD using two large U.S. real-world patient databases:

  • Optum Clinformatics® (nationwide claims data)
  • Northwestern Medicine Enterprise Data Warehouse (NMEDW) (Illinois-based EHR data)

The focus was to determine whether these agents confer a measurable reduction in Alzheimer’s risk and to explore subgroup-specific effects.

Methods: Robust Real-World Evidence Generation

Cohort Design

  • Included patients ≥ 60 years old initiating GLP‑1 RAs, SGLT‑2 inhibitors, or DPP‑4 inhibitors between 2005–2023.
  • Excluded individuals with prior AD, PD, dementia, or major neurological conditions at baseline.
  • Compared three primary drug class pairs:
    1. GLP‑1 RAs vs. DPP‑4 inhibitors
    2. SGLT‑2 inhibitors vs. DPP‑4 inhibitors
    3. GLP‑1 RAs vs. SGLT‑2 inhibitors

Statistical Approach

  • Covariate-adjusted, index-year–stratified Cox models to estimate hazard ratios (HRs) for AD onset.
  • Adjusted for extensive comorbidities, demographic factors, and concurrent antidiabetic therapy.
  • Conducted subgroup analyses by sex, race, and weight class.
  • Performed multiple sensitivity analyses, including propensity score (PS) matching and drug-specific comparisons.

Key Findings: Strong and Consistent Alzheimer’s Risk Reduction

  1. GLP‑1 Receptor Agonists vs. DPP‑4 Inhibitors

  • Significant risk reduction in AD in both datasets: HRs between 0.54 – 0.69, p < 0.001 [[4], [6]].
  • Consistent benefits in female, White, and obese patients.
  • Drug-specific analysis: Liraglutide and Semaglutide showed the strongest associations (HRs as low as 0.23).

  1. SGLT‑2 Inhibitors vs. DPP‑4 Inhibitors

  • Significant AD risk reduction: HRs between 0.32 – 0.67, p < 0.001.
  • Benefits observed across both sexes, White patients, and obese individuals.
  • Dapagliflozin, Canagliflozin, and Empagliflozin all demonstrated significant associations in drug-specific analyses.

  1. GLP‑1 RAs vs. SGLT‑2 Inhibitors

  • No consistent differences in AD risk between these two high-performing classes.

  1. Parkinson’s Disease Outcomes

  • No consistent associations for PD risk reduction across any drug comparisons.

Mechanistic Insights: Why These Agents May Protect the Brain

Preclinical and translational research suggests several neuroprotective pathways for GLP‑1 RAs and SGLT‑2 inhibitors:

  • Blood–brain barrier penetration superior to DPP‑4 inhibitors.
  • Reduction of neuroinflammation, Aβ deposition, and tau pathology.
  • Improvement of vascular health and reduction of ischemic injury.
  • Autophagy and mitophagy regulation, potentially enhancing clearance of neurotoxic proteins.

Clinical Implications for Healthcare Professionals

Potential Dual Benefit in T2DM Patients

For individuals with T2DM—particularly those with cardiovascular risk, obesity, or early cognitive symptoms—GLP‑1 RAs and SGLT‑2 inhibitors may offer both metabolic and neurological protection.

Therapeutic Selection Considerations

Current antidiabetic guidelines prioritize GLP‑1 RAs or SGLT‑2 inhibitors based on cardiovascular and renal profiles. This study suggests that Alzheimer’s disease risk reduction may be another factor to weigh in drug choice, especially in patients with strong AD risk factors.

Limitations to Keep in Mind

  • Observational design – cannot prove causality.
  • Potential for residual confounding from unmeasured variables (e.g., socioeconomic status, education, severity of comorbidities, APOE genotype).
  • AD diagnosis based on clinical coding—no biomarker confirmation.
  • Population limited to insured and healthcare-engaged individuals in the U.S.

Conclusion: A Compelling Case for Further Trials

Real-world data from two large, independent U.S. datasets show that GLP‑1 receptor agonists and SGLT‑2 inhibitors are consistently associated with reduced Alzheimer’s disease risk compared to DPP‑4 inhibitors.
These findings—combined with strong preclinical evidence—support the urgent need for randomized controlled trials to confirm causality and guide therapeutic strategies.

SOURCE / READ THE FULL PAPER  https://doi.org/10.1002/alz.70639


LEARN MORE ABOUT THE MUSLIM WEIGHT MANAGEMENT

 

Share this post